Sunday 18 October 2026
Export PBLS’s income statement to Excel — free account
Parabilis Medicines, Inc.
PBLS
Insiders bought in the last twelve months.
22.75
2.43
−9.65%
Follow PBLS
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
0.52 | 2.84 |
Net Debt/EBITDA |
0.09 | 0.57 |
Debt/Assets |
18.00% | 11.66% |
Debt/Equity |
(0.88) | 0.31 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.66 | 0.64 |
Capex/Depreciation |
(0.10) | (0.59) |
Interest Coverage |
(99.92) | (84.88) |
| 41.06% | 0.00% | |
| (162.50%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
902.27% | (235.19%) |
Average Days of Receivables |
— | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(61.30) | (54.02) |
Cash per Share |
13.70 | 45.48 |
Shareholders Equity per Share |
(8.17) | 29.18 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(8.17) | 29.18 |
Free Cash Flow |
(124.02) | (104.49) |
Working Capital |
(27.43) | 59.80 |
Capital Expenditures |
(0.31) | (0.88) |
Net Current Asset Value |
(67.99) | (0.61) |
| Other line items | ||
Quick Ratio |
0.49 | 2.72 |
Depreciation/Fixed assets |
0.46 | 0.17 |
Cash ROIC |
(481.93%) | (64.58%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(61.15) | (53.57) |
Capex per Share |
(0.15) | (0.45) |
Average Payables |
13.39 | — |
Average Assets |
115.04 | — |
Average Common Equity |
(455.22) | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026